Compare Adaptive Biotechnologies Corp (ADPT) vs Gartner Inc (IT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Gartner Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Gartner Inc trades at $135.26 (market cap $9.43B). The key difference: Gartner Inc is far larger — about 2.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | IT | |
|---|---|---|
Market Cap | $3.33B | $9.43B |
Sector | Health | Technology |
52-Week High | $22.37 | $399.15 |
52-Week Low | $10.24 | $125.68 |
Enterprise Value | $3.19B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Gartner (IT) trades at $140.80, up 3.29% today, with a bearish technical signal but strong fundamental profitability. Recent earnings consistently beat estimates, with Q1 2026 EPS of $3.32 exceeding the $2.99 forecast. The company maintains robust margins, including a 68.99% gross profit margin and 11.44% net income margin, though 2025 net cash flow was negative $210.63 million. Analyst consensus price target is $158.00, suggesting potential upside from current levels.
The stock offers value with a P/E of 13.35 and P/S of 1.54, but high P/B of 142.72 and negative cash flow trends pose risks. Competitive pressures in IT consulting and reliance on enterprise spending are headwinds. Institutional sentiment is mixed with 27.78% buy ratings, indicating cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
